HARMONY is dedicated to advancing equitable, high-quality cancer patient care globally. Stakeholders in oncology agree that harmonizing approval processes and clinical trials globally will benefit patients and save lives. While there is a movement toward harmonisation, there is no focused effort to achieve this end.
The existing disparities in clinical trial accessibility deny many cancer patients potential life-sparing benefits. This disharmony hampers the development and regulatory approval of cancer treatments worldwide. Although the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has provided guidelines and encouraged criteria, their implementation remains unfulfilled. To achieve harmonisation, a unified and collaborative framework is required. Within this framework, success is defined as “A drug approved anywhere will be available everywhere for life-threatening disease”.
It is imperative that we raise awareness about the advantages of globally harmonised clinical trials, unite international experts, and leverage existing networks, organisations, and advocates.
HARMONY, a keystone initiative of the Society for Translational Oncology (STO), is dedicated to saving cancer patients the world over.